BMS 754807

Drug Profile

BMS 754807

Alternative Names: BMS-754807

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Class 2 ring heterocyclic compounds; Amides; Antineoplastics; Pyrazoles; Small molecules
  • Mechanism of Action Insulin-like growth factor-I receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Solid tumours

Most Recent Events

  • 01 Nov 2014 Bristol-Myers Squibb completes a phase II trial in Breast cancer (Combination therapy, Second-line therapy or greater) in USA, Canada and Puerto Rico (NCT01225172)
  • 17 Jun 2013 Bristol-Myers Squibb terminates in its phase I/II trial for Solid tumours (combination therapy) in USA & Canada (NCT00908024)
  • 30 Apr 2013 Bristol-Myers Squibb completes a phase I trial in Solid tumours (monotherapy) in Australia (NCT00569036)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top